CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOACaptura de pantalla 2022 09 14 a las 10.27.10    

Translational medicine in inborn errors of metabolism and other rare genetic diseases

Research summary:

Our group has been focused on the research of inborn errors a metabolism (IEM) for 30 years ago. Inborn errors of metabolism are one of the major groups of rare genetic diseases (1 every 800 newborns have one). The aims are aligned with the international guidelines focused to improve the identification of genetic/genomic causes of rare diseases and the development of advanced therapies. Genomic high-throughput sequencing has dramatically accelerated gene discovery in IEM, transforming Metabolic Medicine. However, more than half of patients remain undiagnosed since examinations are usually restricted to coding sequences, or, if whole genome sequencing (WGS) is performed, diagnosis is prevented since many of the variants detected are of unclear clinical significance.  Our aim is to increase the diagnosis rate for IEM via a multi-omics pipeline of genomic, transcriptomic, and epigenomic data for detecting elusive deep intronic and non-coding variants and comprehensively understanding their functional consequences. Additionally, via long-read PCR-free sequencing, we propose to address the inefficiencies of current technologies when faced with long repetitive elements (LINE), copy number alterations, structural variations or DNA or RNA epigenetic modifications - all of which prevent the detection of (likely) large numbers of variants in the clinical setting. This multi-omics pipeline will be combined with a functional genomics platform for deciphering the clinical impact of splicing defects, non-coding variants and structural variations, using ex vivo cellular models, CRISP/cas9 edition to generate cellular models, and cells differentiated from iPSC-derived fibroblasts for examining genes with tissue-specific expressions. Our second aim is to advance in therapeutic strategies for these orphan diseases (i.e. PMM2-CDG, Methylmalonic aciduria, or hyperglycinemia, among others) based on small chemical compounds (i.e., pharmacological chaperones, proteostasis regulators), drug repurposing, mRNA, and protein therapies. We plan to use differentiated cells from iPSC, generated from patient-derived fibroblasts. We are working on the generation of hepatocyte-like cells, Purkinje-like cells, or astrocyte-like cells as a preclinical cellular platform for testing the efficiency and efficacy of potential drugs and for high throughput drug screening. These cellular models are been used for to study the pathophysiology of the diseases using experimental multi-omics data (transcriptomics, metabolomics, proteomics or genomics data) to generate mathematical models by system biology and artificial neuronal networks. This work will foster and expedite worldwide collaborations aimed at enhancing the clinical usefulness of genetic discoveries and therapeutic strategies in rare diseases. The translational biomedical impact of the group is notable since the identification and characterization of the genetic basis of diseases is a necessary step for implementing tailored treatments in the era of Personalized Precision Medicine in rare diseases.

This project is funded by the following grants: ISCIII PI22/00699  and Collaborative grants from  CIBERER


* For external calls please dial 34 91196 followed by the extension number
Last nameNameLaboratoryExt.*e-mailProfessional category
Arribas Carreira Laura 220 4596/7830  laura.arribas(at)cbm.csic.es Titulado Sup. Actividades Tecn. y Profes. GP1
Gallego Martínez Diana 220 4596/7830   Titulado Sup.de Actividades Técn. y Profes. GP1
Gámez Abascal Alejandra 220 4596/7830 agamez(at)cbm.csic.es Profesor Contratado Universidad, GA
Leal Pérez Mª Fátima 220 4566/7830 fleal(at)cbm.csic.es Contratado CIBER
Navarrete López de Soria Rosa María 220 4566/7830 rnavarrete(at)cbm.csic.es Contratado CIBER
Pérez González Belén 220 4566/7830 bperez(at)cbm.csic.es Profesor Titular Universidad, GA
Rodríguez Pombo Pilar 220 4628 mprodriguez(at)cbm.csic.es Profesor Titular Universidad, GA
Soriano Alejandro 220 4560/7830    
Vilas Lagoa Alicia 220 4560/7830 alicia.vilas(at)cbm.csic.es Titulado Sup.de Actividades Técn. y Profes. GP1

Relevant publications:

  • Alejandro Soriano-Sexto, Diana Gallego, Fátima Leal , Natalia Castejón-Fernández , Rosa Navarrete, Patricia Alcaide, María L. Couce, Elena Martín-Hernández, Pilar Quijada-Fraile, Luis Peña-Quintana, Raquel Yahyaoui, Patricia Correcher, Magdalena Ugarte, Pilar Rodríguez-Pombo, Belén Pérez. Identification of Clinical Variants beyond the Exome in Inborn Errors of Metabolism. Int. J. Mol. Sci – 2022
  • Cristina Segovia-Falquina, Alicia Vilas, Fátima Leal, Francisco Del Caño-Ochoa, Edwin P Kirk, Magdalena Ugarte, Santiago Ramón-Maiques, Alejandra Gámez, Belén Pérez. A functional platform for the selection of pathogenic variants of PMM2 amenable to rescue via the use of pharmacological chaperones: Hum Mutat 2022 Oct;43(10):1430-1442.
  • Briso-Montiano A, Del Caño-Ochoa F, Vilas A, Velázquez-Campoy A, Rubio V*, Pérez B*, Ramón-Maiques S* (* all are corresponding authors). Insight on molecular pathogenesis and pharmacochaperoning potential in phosphomannomutase 2 deficiency, provided by novel human phosphomannomutase 2 structures. J Inherit Metab Dis 2022: 45(2):318-333.
  • Arribas-Carreira L, Dallabona C, Swanson MA, Farris J, Østergaard E, Tsiakas K, Hempel M, Aquaviva-Bourdain C, Koutsoukos S, Stence NV, Magistrati M, Spector EB, Kronquist K, Christensen M, Karstensen HG, Feichtinger RG, Achleitner MT, Lawrence Merritt J, Pérez B, Ugarte M, Grünewald S, Riela AR, Julve N, Arnoux JB, Haldar K, Donnini C, Santer R, Lund AM, Mayr JA, Rodríguez-Pombo P, Van Hove JLK Pathogenic variants in GCSH encoding the moonlighting H-protein cause combined Nonketotic Hyperglycinemia and Lipoate Deficiency.. Hum Mol Genet – 2022.
  • Cristina Segovia-Falquina, Alicia Vilas, Fátima Leal, Francisco Del Caño-Ochoa, Edwin P Kirk, Magdalena Ugarte, Santiago Ramón-Maiques, Alejandra Gámez, Belén Pérez. A functional platform for the selection of pathogenic variants of PMM2 amenable to rescue via the use of pharmacological chaperones. Hum Mutat 2022 Oct;43(10):1430-1442.
  • Briso-Montiano A, A Vilas, E Richard, P Ruiz-Sala, E Morato, LR Desviat, M Ugarte, P Rodríguez-Pombo, B Pérez.Hepatocyte-like cells differentiated from methylmalonic aciduria cblB type induced pluripotent stem cells: A platform for the evaluation of pharmacochaperoning. Biochim Biophys Acta Mol Base Dis 2022 Sep 1;1868(9):166433.
  • A Vilas, P Yuste-Checa, D Gallego, LR Desviat, M Ugarte, C Pérez-Cerda, A Gámez and B Pérez. Proteostasis regulators as potential rescuers of PMM2 activity. Biochim Biophys Acta Mol Basis 2020 Jul 1;1866(7):165777. doi: 10.1016/j.bbadis.2020.165777.
  • Pathogenic variants of DNAJC12 and evaluation of the encoded co-chaperone as a genetic modifier of hyperphenylalaninemia. Gallego Diana, Leal Fátima, Gámez Alejandra, Castro Margarita, Navarrete Rosa, Sánchez-Lijarcio Obdulia, Vitoria Isidro, Bueno-Delgado Marí, Belanger-Quintana Amaya, Morais Ana, Pedrón-Giner Consuelo, García Inmaculada, Campistol Jaum, Artuch Rafael, Alcaide Carlo, Cornejo Verónica, Gil David, Yahyaoui  Raquel,  Desviat Lourdes R., Ugarte Magdalena, Martínez  Aurora, Pérez Belén. Human Mutation 2020 Jul;41(7):1329-1338. doi: 10.1002/humu.24026.
  • Celia Medrano, Ana Vega, Rosa Navarrete, Jesús Ecay,  Rocío Calvo, Samuel Ignacio Pascual, Mónica Ruiz-Pons, LauraToledo,  Inmaculada García-Jiménez, Ignacio Arroyo, Andrea Campo,  M. Luz Couce,  M. Rosario Domingo-Jiménez, M. Teresa García-Silva, Luis González-Gutiérrez-Solana,  Loreto Hierro, Elena Martín-Hernández, Mercedes Martínez-Pardo,  Susana Roldán, Miguel Tomás, Jose C. Cabrera,  Francisco Mártinez-Bugallo,  Lucía Martín-Viota, Isidro Vitoria-Miñana,  Dirk J. Lefeber,  M. Luisa Girós, Mercedes Serrano Gimare,  Magdalena Ugarte, Belén Pérez* and Celia Pérez-Cerdá* (shared authorship). Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain.  Clin Genet  2019 May; 95(5): 615-626.


NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand


What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

  • Accept cookies: if the user presses the acceptance button, this warning will not be displayed again when accessing any page of the portal.
  • Review the cookies policy: the user can access to this page in which the use of cookies is detailed, as well as links to modify the browser settings.

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: